Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
2016 ◽
Vol 34
(15_suppl)
◽
pp. e17503-e17503
2016 ◽
Vol 33
(3)
◽
pp. 401-407
◽